Krystal Biotech's VYJUVEK, a groundbreaking gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Trading at 57x 2024 earnings, Krystal's stock appears expensive but is ...

“We are confident in our ability to address the remaining post-marketing issues, and we believe that this additional exchange with EMA will ultimately maximize benefit and convenience to patients ...

DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. As of October, Krystal secured more than 460 ...

as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

in May 2023 for the treatment of DEB and is marketed and sold in the U.S. under the name VYJUVEK®. For more information on VYJUVEK, see full U.S. Prescribing Information . About Krystal Biotech ...

DEB is a rare and severe monogenic disease that affects the skin and mucosal tissues. It is caused by one or more mutations in a gene called COL7A1. As of October, Krystal secured more than 460 ...

“We are confident in our ability to address the remaining post-marketing issues, and we believe that this additional exchange with EMA will ultimately maximize benefit and convenience to patients ...

The FDA has approved Krystal Biotech’s gene therapy Vyjuvek for dystrophic epidermolysis bullosa (DEB), a rare genetic disease characterised by fragile skin that can split and blister even with ...

Mysterious portrait of Fernando, aka Deborah Krystal, the glittering and poetic performer of the Lisbon club Finalmente, where he has been performing every night over thirty years in golden dresses.

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling ...